Evidence map›Paper›PMID 31385111›Full record

ArticlePharmaceutical research2019

Octreotide Nanoparticles Showed Affinity for In Vivo MIA Paca-2 Inducted Pancreas Ductal Adenocarcinoma Mimicking Pancreatic Polypeptide-Secreting Tumor of the Distal Pancreas (PPoma).

Thaís Ligiéro Braga, Suyene Rocha Pinto, Sara Rhaissa Rezende Dos Reis, Filipe Leal Portilho, Aline Oliveira da Silva de Barros, Emerson Soares Bernardes, Sofia Nascimento Dos Santos, Luciana Magalhães Rebelo Alencar, Eduardo Ricci-Junior, Ralph Santos-Oliveira

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. MST1/2 in inflammation and immunity.Cell adhesion & migration · 2023
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Thaís Ligiéro BragaBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil.
Suyene Rocha PintoBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil.
Sara Rhaissa Rezende Dos ReisBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil.
Filipe Leal PortilhoBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil.
Aline Oliveira da Silva de BarrosBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil.
Emerson Soares BernardesCentro de Radiofarmácia, Instituto de Pesquisas Energéticas e Nucleares, São Paulo, Brazil.
Sofia Nascimento Dos SantosCentro de Radiofarmácia, Instituto de Pesquisas Energéticas e Nucleares, São Paulo, Brazil.
Luciana Magalhães Rebelo AlencarBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil.
Eduardo Ricci-JuniorFaculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Ralph Santos-OliveiraBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil. presidenciaradiofarmacia@gmail.com.ORCID http://orcid.org/0000-0002-0905-481X
Nuclear Engineering Institute · BRInstituto de Pesquisas Energéticas e Nucleares · BRUniversidade Estadual da Zona Oeste · BRUniversidade Federal do Rio de Janeiro · BR

Funding

CAPES PROEXT-UERJ-PPGBCNPq Universal
6 · The paper itself

Abstract

purposePancreatic Polypeptide-secreting tumor of the distal pancreas (PPoma) is a rare, difficult and indolent type of cancer with a survival rate of 5-year in only 10% of all cases. The PPoma is classified as a neuroendocrine tumor (NET) not functioning that overexpresses SSTR 2 (somatostatin receptor subtype 2). Thus, in order to improve the diagnosis of this type of tumor, we developed nanoparticulate drug carriers based on poly-lactic acid (PLA) polymer loaded with octreotide and radiolabeled with Technetium-99 m (

methodsPLA/PVA octreotide nanoparticles were developed by double-emulsion technique. These nanoparticles were characterized by Atomic Force Microscopy (AFM) and Dynamic Light Scattering (DLS) and radiolabeled with 99mTc by the direct via forming

resultsThe results showed that a 189 nm sized nanoparticle were formed with a PDI of 0,097, corroborating the monodispersive behavior. These nanoparticles were successfully radiolabeled with 99mTc showing uptake by the inducted tumor. The MTT assay corroborated the safety of the nanosystem for the cells.

conclusionThe results support the use of this nanosystem (

Indexed as

AnimalsCarcinoma, Pancreatic DuctalCell Line, TumorCell SurvivalHumansMaleMice, Inbred BALB CMice, NudeNanoparticlesOctreotidePancreasPancreatic NeoplasmsPancreatic PolypeptideParticle SizePolyestersRadionuclide ImagingOctreotidePancreatic PolypeptidePolyesterspoly(lactide)RadiopharmaceuticalsReceptors, SomatostatinSSTR2 protein, humanTechnetiumimaging agentnanoradiopharmaceuticalsoctreotidePPomaradiopharmacy

Identifiers

PMID31385111
OpenAlexW2966501946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.